Some of the research published by Bionor Pharma and collaborators to date:

-The therapeutic HIV Env C5/gp41 vaccine candidate Vacc-C5 induces specific T cell regulation in a phase I/II clinical study. Brekke K, Sommerfelt MA, Ökvist M, Dyrhol-Riise AM, Kvale D. BMC infectious Diseases 2017 17:228

-The combined effect of Vacc-4x/rhuGM-CSF vaccination and romidepsin on the HIV-1 reservoir: a phase Ib/IIa, single group, clinical trial. Leth S, Schleimann MH, Nissen SK, Højen JF, Olesen R, Graversen ME, Jørgensen S, Kjær AS, Denton PW, VanBelzen DJ, Mørk A, Sommerfelt MA, Krogsgaard K, Østergaard L, Rasmussen TA, Tolstrup M, Søgaard OS. Lancet HIV 2016 3:e463-e472.

-A Case for preART-Adjusted Endpoints in HIV Therapeutic Vaccine Trials. Huang, Y., Zhang, L., Jolliffe D., Hovden AO., Ökvist, M., Pantaleo, G., Sommerfelt M A. Vaccine 2016 34:1282-1288.

-The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo. Søgaard OS, Graversen ME, Leth S, Olesen R, Brinkmann CR, Nissen SK, Kjaer AS, Schleimann MH, Denton PW, Hey-Cunningham WJ, Koelsch KK, Pantaleo G, Krogsgaard K, Sommerfelt M, Fromentin R, Chomont N, Rasmussen TA, Østergaard L, Tolstrup M. PLoS Pathog. 2015 Sept. 17;11(9):e1005142.

-Intranasal administration of a therapeutic HIV vaccine (Vacc-4x) induces dose-dependent systemic and mucosal immune responses in a randomized controlled trial. Brekke K, Lind A, Holm-Hansen C, Haugen IL, Sørensen B, Sommerfelt M, Kvale D. PLoS One. 2014 Nov 14;9(11):e112556

-Boosters of a therapeutic HIV-1 vaccine induce divergent T cell responses related to regulatory mechanisms. Lind A, Brekke K, Sommerfelt M, Holmberg JO, Aass HC, Baksaas I, Sørensen B, Dyrhol-Riise AM, Kvale D. Vaccine 2013 Sep 23;31(41):4611-8.

-Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial. Pollard RB, Rockstroh JK, Pantaleo G, et al.  Lancet Infect Dis 2014. published online Feb 11.

-Boosters of a therapeutic HIV-1 vaccine induce divergent T cell responses related to regulatory mechanisms. Lind A, Brekke K, Sommerfelt M, Holmberg JO, Aass HC, Baksaas I, Sørensen B, Dyrhol-Riise AM, Kvale D.Vaccine. 2013 Sep 23;31(41):4611-8

-The HIV-1 gp120 C5 Region Shows HLA-like Properties for Immune Activation that May Be Masked by Antibodies.Sørensen B,. Sommerfelt MA, Stjernholm G, Smith PL,Ökvist M, Brandsdal BO, Hovden AOH, Zeldis J, Hoddevik G, Redfield R, Dalgleish A. AIDS Res. Hum. Retroviruses 2013.29 (11):142. Supplement. Abstract P13.19
Abstract on page A-142 Nr P13.19

-Delayed-type hypersensitivity responses to HIV Gag p24 relate to clinical outcome after peptide-based therapeutic immunization for chronic HIV infection.Kran AM, Sommerfelt MA, Baksaas I, Sørensen B, Kvale D. APMIS. 2012 Mar;120(3):204-9

-Intradermal Vaccination of HIV-infected Patients with Short HIV Gag p24-like Peptides Induces CD4+ and CD8+ T cell Responses Lasting more than 7 Years. Lind A, Sommerfelt MA, Holmberg JO, Baksaas I, Sørensen B, Kvale D. Scand. J. Inf. Dis. 2012 44(8):566-72

-Oral presentation:Quality of T-cell responses versus reduction in viral load: results from an exploratory phase II clinical study of Vacc-4x, a therapeutic HIV vaccine K Ellefsen-Lavoie, J Rockstroh, R Pollard, G Pantaleo, D Podzamczer, D Asmuth, J van Lunzen, K Arastéh, D Schürmann, B Peters, B Clotet, D Hardy, A Lazzarin, J Gatell, MA Sommerfelt, I Baksaas, V Wendel-Hansen, B Sørensen Retrovirology 2012, 9(Suppl 2):O66 (13 September 2012)

-Low frequency of amino acid alterations following therapeutic immunization with HIV-1 Gag p24-like peptides Kran A-MB, Jonassen TØ, Sommerfelt MA, Løvgården L, Sørensen B, Kvale D. (2010). AIDS 24(17): 2609-18

-Sommerfelt MA, Dalgleish AG, Wendel-Hansen V, Sørensen B. (2013). Vacc-4x and Vacc-C5: Two peptide-based therapeutic HIV vaccine candidates. Conference Abstract from Institute of Human Virology Annual Conference in 2011. Published in JAIDS 62 Supplement 1

-Prospects for HIV-1 therapeutic immunisation and vaccination: the potential contribution of peptide immunogensSommerfelt MA, Sørensen B. Expert Opin Biol Ther. 2008 Jun;8(6):745-57.

-Long-term HIV-specific responses and delayed resumption of antiretroviral therapy after peptide immunization targeting dendritic cellsKran AM, Sørensen B, Sommerfelt MA, Nyhus J, Baksaas I, Kvale D. AIDS. 2006 Feb 28;20(4):627-30

-Multiple antigen concentrations in delayed-type hypersensitivity (DTH) and response diversity during and after immunization with a peptide-based HIV-1 immunotherapy candidate (Vacc-4x).Nyhus J, Kran AM, Sommerfelt MA, Baksaas I, Sørensen B, Kvale D. Vaccine. 2006 Mar 6;24(10):1543-50.

-Reduced viral burden amongst high responder patients following HIV-1 p24 peptide-based therapeutic immunization.Kran AM, Sommerfelt MA, Sørensen B, Nyhus J, Baksaas I, Bruun JN, Kvale D. Vaccine. 2005 Jul 1;23(31):4011-5.

-Divergent in vitro and in vivo correlates of HIV-specific T-cell responses during onset of HIV viraemiaKvale D, Kran AM, Sommerfelt MA, Nyhus J, Baksaas I, Bruun JN, Sørensen B. AIDS. 2005 Mar 24;19(6):563-7.

-Novel peptide-based HIV-1 immunotherapy. Sommerfelt MA, Nyhus J, Sørensen B. Expert Opin Biol Ther. 2004 Mar;4(3):349-61.

-Phase I trial of a therapeutic HIV type 1 vaccine, Vacc-4x, in HIV type 1-infected individuals with or without antiretroviral therapy.Åsjö B, Stavang H, Sørensen B, Baksaas I, Nyhus J, Langeland N. AIDS Res. Hum. Retroviruses. 2002 Dec 10;18(18):1357-65